Aila Biotech is a Cambridge-based spin-out developing a new class of brain-targeted immunotherapies for neuroinflammatory disease. Our patented platform enables immune-modulating biologics to be produced locally at sites of inflammation within the brain, overcoming both the blood–brain barrier and peripheral off-target toxicity.

​

Aila Biotech is incorporated and holds an option on the core patent portfolio. We are currently raising a £5.75m Seed round to progress our flagship product to first-in-human clinical trials and advance additional high-value biologics within the platform.

 

Aila Biotech combines world-leading neuroimmunology with an experienced clinical, biotech, and regulatory team. Our mission is to change the way neuroinflammatory diseases are treated to transform the lives of patients.